StockNews.com Upgrades Sanofi (NASDAQ:SNY) to “Strong-Buy”

StockNews.com upgraded shares of Sanofi (NASDAQ:SNY) from a buy rating to a strong-buy rating in a research note released on Thursday morning.

Other research analysts also recently issued research reports about the company. Citigroup raised Sanofi to a strong-buy rating in a research note on Tuesday, September 17th. Argus raised their target price on shares of Sanofi from $55.00 to $60.00 and gave the stock a buy rating in a research note on Friday, July 26th. Three equities research analysts have rated the stock with a hold rating, one has assigned a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of Moderate Buy and an average price target of $57.50.

Sanofi Stock Performance

Shares of NASDAQ SNY opened at $57.65 on Thursday. The company has a current ratio of 1.00, a quick ratio of 0.65 and a debt-to-equity ratio of 0.17. Sanofi has a 12-month low of $42.63 and a 12-month high of $58.97. The firm has a market capitalization of $146.01 billion, a price-to-earnings ratio of 28.97, a price-to-earnings-growth ratio of 1.62 and a beta of 0.60. The firm has a 50 day moving average of $55.04 and a 200 day moving average of $50.82.

Sanofi (NASDAQ:SNY) last issued its quarterly earnings data on Thursday, July 25th. The company reported $0.93 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.88 by $0.05. Sanofi had a net margin of 9.60% and a return on equity of 26.29%. The firm had revenue of $10.75 billion during the quarter, compared to the consensus estimate of $16.86 billion. During the same quarter in the previous year, the firm posted $0.95 EPS. The company’s revenue for the quarter was up 7.8% compared to the same quarter last year. On average, research analysts anticipate that Sanofi will post 4.26 earnings per share for the current year.

Institutional Trading of Sanofi

Several institutional investors and hedge funds have recently added to or reduced their stakes in SNY. Congress Wealth Management LLC DE bought a new position in Sanofi in the 4th quarter worth approximately $226,000. Catalytic Wealth RIA LLC purchased a new position in shares of Sanofi in the fourth quarter worth $346,000. Manhattan West Asset Management LLC boosted its position in shares of Sanofi by 57.6% during the fourth quarter. Manhattan West Asset Management LLC now owns 67,928 shares of the company’s stock worth $3,378,000 after acquiring an additional 24,817 shares during the last quarter. Scotia Capital Inc. grew its stake in Sanofi by 186.8% during the fourth quarter. Scotia Capital Inc. now owns 13,411 shares of the company’s stock valued at $667,000 after acquiring an additional 8,735 shares in the last quarter. Finally, Jones Financial Companies Lllp increased its holdings in Sanofi by 197.5% in the 4th quarter. Jones Financial Companies Lllp now owns 1,050 shares of the company’s stock valued at $52,000 after acquiring an additional 697 shares during the last quarter. Institutional investors own 10.04% of the company’s stock.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.